Celltrion resubmits application for marketing approval of trastuzumab biosimilar

Jun 17, 2018

Celltrion resubmits application for marketing approval of trastuzumab biosimilar to the FDA. This follows CRLs from the FDA related to the February warning letter regarding Celltrion’s manufacturing facility in South Korea.

Print Page Mail Article